416 related articles for article (PubMed ID: 8813137)
1. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
[TBL] [Abstract][Full Text] [Related]
2. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
4. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
Borovitskaya AE; D'Arpa P
Oncol Res; 1998; 10(5):271-6. PubMed ID: 9802062
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
[TBL] [Abstract][Full Text] [Related]
6. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B.
Tsao YP; D'Arpa P; Liu LF
Cancer Res; 1992 Apr; 52(7):1823-9. PubMed ID: 1312900
[TBL] [Abstract][Full Text] [Related]
7. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
Sané AT; Bertrand R
Cancer Res; 1999 Aug; 59(15):3565-9. PubMed ID: 10446962
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
Zhou Y; Gwadry FG; Reinhold WC; Miller LD; Smith LH; Scherf U; Liu ET; Kohn KW; Pommier Y; Weinstein JN
Cancer Res; 2002 Mar; 62(6):1688-95. PubMed ID: 11912141
[TBL] [Abstract][Full Text] [Related]
9. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Matsui SI; Arredondo MA; Wrzosek C; Rustum YM
Cancer Res; 1996 Oct; 56(20):4715-23. PubMed ID: 8840989
[TBL] [Abstract][Full Text] [Related]
10. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Fujimori A; Gupta M; Hoki Y; Pommier Y
Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
[TBL] [Abstract][Full Text] [Related]
11. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Szumiel I
Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569
[TBL] [Abstract][Full Text] [Related]
12. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Valenti M; Nieves-Neira W; Kohlhagen G; Kohn KW; Wall ME; Wani MC; Pommier Y
Mol Pharmacol; 1997 Jul; 52(1):82-7. PubMed ID: 9224816
[TBL] [Abstract][Full Text] [Related]
13. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines.
Wang W; Heideman L; Chung CS; Pelling JC; Koehler KJ; Birt DF
Mol Carcinog; 2000 Jun; 28(2):102-10. PubMed ID: 10900467
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
15. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
Beidler DR; Cheng YC
Mol Pharmacol; 1995 May; 47(5):907-14. PubMed ID: 7538195
[TBL] [Abstract][Full Text] [Related]
16. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells.
Hennequin C; Giocanti N; Balosso J; Favaudon V
Cancer Res; 1994 Apr; 54(7):1720-8. PubMed ID: 8137287
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint?
Wang Y; Perrault AR; Iliakis G
Cancer Res; 1997 May; 57(9):1654-9. PubMed ID: 9135002
[TBL] [Abstract][Full Text] [Related]
18. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
19. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage.
Shimizu T; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1995 Jan; 55(2):228-31. PubMed ID: 7812949
[TBL] [Abstract][Full Text] [Related]
20. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
